- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00003123
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes
RATIONALE: Amifostine may be effective in helping blood counts return to normal in treating patients with myelodysplastic syndrome.
PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with advanced myelodysplastic syndrome.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES: I. Determine the overall hematologic response rate to amifostine in patients with advanced myelodysplastic syndrome. II. Determine the toxic effects of amifostine in these patients.
OUTLINE: This is an open label study. Patients receive intravenous amifostine over 15 minutes three times a week. Patients failing to respond by 8 weeks undergo dose escalation. Nonresponding patients are removed from the study by 12 weeks. Therapy is continued for up to six months in responding patients. Patients are observed for duration of response upon therapy discontinuation. Patients who relapse will have therapy resumed at the previous dose. Patients will be followed until death.
PROJECTED ACCRUAL: A maximum of 36 patients will be accrued.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Michigan
-
Clinton Township, Michigan, Forenede Stater, 48038-1657
- Osteopathic Medical Oncology and Hematology, P.C.
-
Detroit, Michigan, Forenede Stater, 48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Garden City, Michigan, Forenede Stater, 48135
- Garden City Hospital
-
Marquette, Michigan, Forenede Stater, 49855
- Marquette General Hospital
-
Southfield, Michigan, Forenede Stater, 48075
- Providence Hospital Cancer Center
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS: Histologically proven advanced myelodysplastic syndrome (MDS), including: Refractory anemia Refractory anemia with ringed sideroblasts Refractory anemia with excess blasts Refractory anemia with excess blasts in transformation MDS with at least bicytopenia No chronic myelomonocytic leukemia No acute leukemia
PATIENT CHARACTERISTICS: Age: 17 and over Performance Status: ECOG 0-2 Life Expectancy: Greater than 6 months Hematopoietic: Hemoglobin less than 8.5 g/dL Absolute granulocyte count less than 1,000 g/dL Platelet count less than 70,000/mm3 Hepatic: No major hepatic problems Renal: No major renal problems Cardiovascular: No major cardiac disease Other: Prior transfusion of blood products is allowed Not pregnant Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Prior cytokine therapy is allowed Chemotherapy: No prior chemotherapy Endocrine therapy: Prior steroid therapy is allowed Radiotherapy: Not specified Surgery: Not specified Other: Prior leucovorin calcium and pyridoxine allowed
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Howard R. Terebelo, DO, Providence Hospital
Publikationer og nyttige links
Generelle publikationer
- Terebelo H, Marsico D, Shurafa M, et al.: A phase II trial of amifostine in patients with advanced myelodysplastic syndromes. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A82, 23a, 1999.
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CDR0000065882
- PH-890
- ALZA-97-018-ii
- NCI-V97-1350
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myelodysplastiske syndromer
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mand med sexkromosommosaicismeForenede Stater
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
Kliniske forsøg med amifostin trihydrat
-
Children's Oncology GroupNational Cancer Institute (NCI)AfsluttetMyelodysplastiske syndromer | Myelodysplastiske/myeloproliferative neoplasmerForenede Stater, Canada, Australien, Puerto Rico
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)AfsluttetUspecificeret fast tumor hos voksne, protokolspecifik | Gestationel trofoblastisk tumor | Neurotoksicitet | Perifer neuropatiForenede Stater
-
Rush North Shore Medical CenterAfsluttetUspecificeret fast tumor hos voksne, protokolspecifik | Lægemiddel-/agenttoksicitet efter væv/organForenede Stater
-
University of ArizonaNational Cancer Institute (NCI)AfsluttetProstatakræft | StrålingstoksicitetForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AfsluttetBrystkræft | Livmoderhalskræft | Lungekræft | Prostatakræft | Uspecificeret fast tumor hos voksne, protokolspecifik | NeurotoksicitetForenede Stater
-
Northwestern UniversityNational Cancer Institute (NCI)AfsluttetLivskvalitet | LivmoderhalskræftForenede Stater
-
National Cancer Institute (NCI)AfsluttetProstatiske neoplasmerForenede Stater
-
European Organisation for Research and Treatment...UkendtMyelodysplastiske syndromer | AnæmiBelgien, Schweiz, Tjekkiet, Portugal, Østrig, Holland, Slovakiet
-
University of TennesseeAfsluttetHoved- og halskræft | Strålingstoksicitet | Orale komplikationer | Lægemiddel-/agenttoksicitet efter væv/organForenede Stater
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)AfsluttetLivmoderhalskræft | StrålingstoksicitetForenede Stater